3 Top Value Plays for Long-Term Investors

Looking for a value play? If so, National Bank of Canada (TSX:NA), Cameco Corporation (TSX:CCO)(NYSE:CCJ), and Concordia Healthcare Corp. (TSX:CXR)(NASDAQ:CXRX) are great options.

| More on:
The Motley Fool
You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

If you’re looking to add a value-based investment to your portfolio, you’ve come to the right place. I’ve scoured the market and found three stocks from three different industries that are trading at inexpensive valuations compared with their five-year and industry averages, so let’s take a quick look to determine if one or more of them could fulfill your portfolio’s needs.

1. National Bank of Canada

National Bank of Canada (TSX:NA) is Canada’s sixth-largest bank with approximately $216.1 billion in total assets.

At today’s levels, its stock trades at just 8.6 times fiscal 2016’s estimated earnings per share of $4.76 and only 8.1 times fiscal 2017’s estimated earnings per share of $5.05, both of which are inexpensive compared with its five-year average price-to-earnings multiple of 10.1 and its industry average multiple of 12.9.

At the very least, I think National Bank’s stock should trade at 10 times earnings, which would place its shares upwards of $50 by the conclusion of fiscal 2017, representing upside of more than 22% from current levels.

Also, the company pays a quarterly dividend of $0.54 per share, or $2.16 per share annually, giving its stock a 5.3% yield.

2. Cameco Corporation

Cameco Corporation (TSX:CCO)(NYSE:CCJ) is one of the world’s largest producers of uranium, providing about 16% of the world’s total production, and it is one of the leading providers of nuclear fuel processing services.

At today’s levels, its stock trades at just 16.5 times fiscal 2015’s estimated earnings per share of $1.05 and only 12.9 times fiscal 2016’s estimated earnings per share of $1.34, both of which are inexpensive compared with its five-year average price-to-earnings multiple of 100.8 and its industry average multiple of 21.7.

At the very least, I think Cameco’s stock should trade at 18 times earnings, which would place its shares upwards of $24 by the conclusion of fiscal 2016, representing upside of more than 38% from current levels.

In addition, the company pays a quarterly dividend of $0.10 per share, or $0.40 per share annually, giving its stock a 2.3% yield. 

3. Concordia Healthcare Corp.

(All figures are in U.S. dollars)

Concordia Healthcare Corp. (TSX:CXR)(NASDAQ:CXRX) is a diverse healthcare company focused on legacy pharmaceutical products and orphan drugs.

At today’s levels, its stock trades at just 8.7 times fiscal 2015’s estimated earnings per share of $4.50 and a mere 6.2 times fiscal 2016’s estimated earnings per share of $6.37, both of which are inexpensive compared with its five-year average price-to-earnings multiple of 149.3 and its industry average multiple of 31.2.

At the very last, I think Concordia’s stock should trade at eight times earnings, which would place its shares around $51 by the conclusion of fiscal 2016, representing upside of more than 30% from current levels.

Also, the company pays a quarterly dividend of $0.075 per share, or $0.30 per share annually, giving its stock a 0.8% yield.

Should one of these stocks be atop your buy list?

National Bank of Canada, Cameco, and Concordia Healthcare are three of the top value plays in their respective industries. Foolish investors should strongly consider establishing positions in one of them today.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Joseph Solitro has no position in any stocks mentioned.

More on Investing

Investing

KM Throwaway Post

Read more »

Investing

Carlos Test Yoast Metadata

Read more »

Investing

KM Ad Test

This is my excerpt.

Read more »

Investing

Test post for affiliate partner mockups

Updated: 9/17/2024. This post was not sponsored. The views and opinions expressed in this review are purely those of the…

Read more »

Investing

Testing Ecap Error

Premium content from Motley Fool Stock Advisor We here at Motley Fool Stock Advisor believe investors should own at least…

Read more »

Investing

TSX Today: Testing the Ad for James

la la la dee dah.

Read more »

Lady holding remote control pointed towards a TV
Investing

2 Streaming Stocks to Buy Now and 1 to Run From

There are streaming stocks on the TSX that are worth paying attention to in 2023 and beyond.

Read more »

A red umbrella stands higher than a crowd of black umbrellas.
Stocks for Beginners

Top Recession-Resilient TSX Stocks to Buy With $3,000

It's time to increase your exposure to defensives!

Read more »